Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

被引：0
|
作者：
Vitale, Nuzzo Pier
Pond, Gregory Russell
Abou Alaiwi, Sarah
Nassar, Amin
Flippot, Ronan
Choueiri, Toni K.
Harshman, Lauren Christine
Sonpavde, Guru
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Hop Piti Salpetriere, Lab Avec Fdn, Paris, France
[5] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[6] Harvard Med Sch, Boston, MA 02115 USA
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16038
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management
    Muntyanu, Anastasiya
    Netchiporouk, Elena
    Gerstein, William
    Gniadecki, Robert
    Litvinov, Ivan V.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2021, 25 (01) : 59 - 76
  • [42] Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Liang, Yao
    Maeda, Osamu
    Ando, Yuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, : 365 - 375
  • [43] Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors
    Byrne, Margaret M.
    Lucas, Mathew
    Pai, Lori
    Breeze, Janis
    Parsons, Susan K.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (06) : 650 - 657
  • [44] Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
    Cheema, Parneet K.
    Iafolla, Marco A. J.
    Abdel-Qadir, Husam
    Bellini, Andrew B.
    Chatur, Nazira
    Chandok, Natasha
    Comondore, Vikram R.
    Cunningham, Morven
    Halperin, Ilana
    Hu, Anne B.
    Jaskolka, Diana
    Darvish-Kazem, Saeed
    Khandaker, Masud H.
    Kitchlu, Abhijat
    Sachdeva, Jasdip S.
    Shapera, Shane
    Woolnough, Nicholas R. J.
    Nematollahi, Massey
    CURRENT ONCOLOGY, 2024, 31 (10) : 6356 - 6383
  • [45] Endocrine immune-related adverse effects of immune-checkpoint inhibitors
    Trevisani, Viola
    Iughetti, Lorenzo
    Lucaccioni, Laura
    Predieri, Barbara
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2023, 18 (05) : 441 - 451
  • [46] COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)
    Zheng, Y.
    Kim, R.
    Yu, T.
    Dreyfus, J.
    Gayle, J. A.
    Wassel, C. L.
    Phatak, H.
    George, S.
    VALUE IN HEALTH, 2019, 22 : S469 - S469
  • [47] Immune-related cutaneous adverse events associated with immune-checkpoint inhibitors: Our experience
    Pinilla-Martin, Belen
    Sanchez-Velazquez, Alba
    Vico-Alonso, Cristina
    Aragon-Miguel, Raquel
    Calleja-Algarra, Alba
    Jose Andres-Lencina, Juan
    Burillo-Martinez, Sara
    Tous-Romero, Fatima
    Maronas-Jimenez, Lidia
    Luis Ortiz-Romero, Pablo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB223 - AB223
  • [48] IMMUNE-RELATED ADVERSE EVENTS FOLLOWING IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Zhu, Kaiwen
    Niu, Chengu
    Liu, Hongli
    Okolo, Patrick
    GASTROENTEROLOGY, 2023, 164 (06) : S1431 - S1432
  • [49] Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience
    Samanci, N. S.
    Oruc, K.
    Bedir, S.
    Celik, E.
    Degerli, E.
    Derin, S.
    Demirelli, F. H.
    Ozguroglu, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Healthcare resource utilization (HCRU) and costs in patients (pts) with advanced cancer treated with immune checkpoint inhibitors (ICIs) who experienced select immune-related adverse events (irAEs)
    George, S.
    Zheng, Y.
    Bell, E. J.
    Engel-Nitz, N. M.
    White, J. C.
    Lal, L. S.
    Kim, R.
    Krulewicz, S.
    Smith, J.
    Liu, F. X.
    ANNALS OF ONCOLOGY, 2020, 31 : S968 - S969
12345